Company profile · Biotech & medical
逸達生物科技股份有限公司 · 6576
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
Foresee Pharmaceuticals is a biopharmaceutical company that develops new drugs.[1]
The company focuses its research and development on a Stabilized Injectable Formulation long-acting injectable technology and preclinical and clinical first-in-class New Chemical Entity programs targeting rare and common severe diseases.[2]
Its product portfolio includes CAMCEVI, a long-acting injectable for the treatment of advanced prostate cancer, as well as programs for central precocious puberty and neurology and psychiatry drugs.[2]
The company also develops oral small molecule drugs such as aderamastat for inflammatory and fibrotic diseases and mirivadelgat for pulmonary hypertension associated with interstitial lung diseases.[2]
Foresee Pharmaceuticals is based in Taiwan and the United States.[2]
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$125m | +397.5% | +1895.4% |
2024-11 to 2026-10, monthly revenue.
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | −NT$27m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
| Full English name | Foresee Pharmaceuticals Co., Ltd. |
|---|---|
| Chinese name | 逸達生物科技股份有限公司 |
| Stock code | 6576 (TPEx) |
| Industry | Biotech & medical |
| Founded | 08 Feb 2013 |
| Listed | 29 Jun 2018 |
| Paid-in capital | NT$1.6bn |
| Chairman | 簡銘達 |
| President | 簡銘達 |
| Headquarters | 9F-2., No.19-3, Sanchong Rd., Nangang Dist., Taipei City 115, Taiwan (R.O.C.) |
| Website | https://www.foreseepharma.com |
| Official business description | 新藥研發 |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Generated 2026-11-11 00:39.